BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Liu Y, Wei R, Hong TP. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(27): 9090-9097 [PMID: 25083081 DOI: 10.3748/wjg.v20.i27.9090]
URL: https://www.wjgnet.com/1007-9327/full/v20/i27/9090.htm
Number Citing Articles
1
Xiaotong Kong, Jianjian Wang, Yuze Cao, Xiaoyu Lu, Huixue Zhang, XiaoMing Zhang, Chunrui Bo, Ming Bai, Shuang Li, Yang Jiao, Lihua Wang. Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosisMedicine 2022; 101(11) doi: 10.1097/MD.0000000000029107
2
Saurabh Srivastava, Amit Gupta, Deepak Sharma, Anuj Maheshwari, Nadima Shaikeh, Rakesh Sahay, Noel C Barengo. Effect of glucagon on lipid metabolismJournal of Diabetology 2023; 14(Supplement 1): S25 doi: 10.4103/jod.jod_99_23
3
Tao Zhang, Yingli Nie, Jiliang Wang. The emerging significance of mitochondrial targeted strategies in NAFLD treatmentLife Sciences 2023; 329: 121943 doi: 10.1016/j.lfs.2023.121943
4
Nicholas W. S. Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin, Kris V. Kowdley. Nonalcoholic Steatohepatitis Drug Development Pipeline: An UpdateSeminars in Liver Disease 2022; 42(03): 379 doi: 10.1055/a-1877-9656
5
Haoran Jiang, Linquan Zang. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLDCurrent Pharmaceutical Design 2024; 30(2): 100 doi: 10.2174/0113816128283153231226103218
6
Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASHCurrent Topics in Medicinal Chemistry 2023; 23(21): 2027 doi: 10.2174/1568026623666230714113808
7
Hsin-Hsien Yu, Hao-Chen Wang, Mao-Chih Hsieh, Ming-Che Lee, Bor-Chyuan Su, Yan-Shen Shan, Si Qin. Exendin‐4 Attenuates Hepatic Steatosis by Promoting the Autophagy‐Lysosomal PathwayBioMed Research International 2022; 2022(1) doi: 10.1155/2022/4246086
8
Zhiyu Li, Chao Cui, Liang Xu, Mingfeng Ding, Yinghui Wang. Metformin suppresses metabolic dysfunction-associated fatty liver disease by ferroptosis and apoptosis via activation of oxidative stressFree Radical Research 2024; 58(11): 686 doi: 10.1080/10715762.2024.2417279
9
Masoud Nouri-Vaskeh, Neda Khalili, Amirreza Khalaji, Pouya Behnam, Leila Alizadeh, Sara Ebrahimi, Neda Gilani, Mehdi Mohammadi, Seyed Alisalar Madinehzadeh, Mohammad Zarei. Circulating glucagon-like peptide-1 level in patients with liver cirrhosisArchives of Physiology and Biochemistry 2023; 129(2): 373 doi: 10.1080/13813455.2020.1828479
10
Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae, Yong‐ho Lee. A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiomeHepatology 2022; 75(6): 1523 doi: 10.1002/hep.32235
11
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01119-3
12
Qin Pan, Jian-Gao Fan, Yusuf Yilmaz. Pathogenetic Pathways in Nonalcoholic Fatty Liver DiseaseClinics in Liver Disease 2023; 27(2): 317 doi: 10.1016/j.cld.2023.01.013